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ABSTRACT
An association has been reported between miR-34a-5p and several types of cancer. 
Specifically, in this study, using systematic observations of multi-drug sensitive (G-
292 and MG63.2) and resistant (SJSA-1 and MNNG/HOS) osteosarcoma (OS) cell lines, 
we showed that miR-34a-5p promotes the multi-drug resistance of OS through the 
receptor tyrosine kinase CD117, a direct target of miR-34a-5p. Consistently, the siRNA-
mediated repression of CD117 in G-292 and MG63.2 cells led to a similar phenotype that 
exhibited all of the miR-34a-5p mimic-triggered changes. In addition, the activity of the 
MEF2 signaling pathway was drastically altered by the forced changes in the miR-34a-
5p or CD117 level in OS cells. Furthermore, si-CD117 suppressed the enhanced colony 
and sphere formation, which is in agreement with the characteristics of a cancer stem 
marker. Taken together, our data established CD117 as a direct target of miR-34-5p 
and demonstrated that this regulation interferes with several CD117-mediated effects 
on OS cells. In addition to providing new mechanistic insights, our results will provide 
an approach for diagnosing and chemotherapeutically treating OS.
INTRODUCTION
MiRNAs are a class of small non-coding regulatory 
RNA molecules that have been shown to be involved in a 
wide range of biological processes [1]. The dysregulation 
of miRNAs has been associated with the development 
of numerous diseases, including cancer. The abnormal 
expression of miRNAs in cancer contributes to every 
aspect of tumor biology [2, 3], including drug resistance 
[4], which remains a major obstacle to effective treatment. 
Numerous mechanisms have been found that mediate 
drug resistance, including decreased intracellular 
drug accumulation, drug inactivation, enhanced DNA 
repair, perturbations in signal transduction pathways, 
apoptosis and autophagy related drug resistance, miRNA 
dysregulation and cancer stem cell (CSC)-mediated drug 
resistance [5]. To date, much effort has been exerted to 
analyze the role of miRNAs in the development of drug 
resistance in various types of cancers. For instance, a 
correlation between the overexpression of miR-21 in 
colorectal cancer and decreased sensitivity to fluorouracil 
(5-FU) was reported [6]. In addition, miR-130a was up-
regulated in SKOV3/DDP cells compared with SKOV3 
cells, and miR-130a inhibition could overcome cisplatin 
resistance by regulating the MDR1/P-gp pathway [7]. The 
expression of miR-140 was involved in the drug resistance 
to osteosarcoma (OS) xenografts through reduced cell 
proliferation via G1 and G2 phase arrest [8].
An association has previously been reported 
between miR-34a, a well-studied miRNA, and several 
Oncotarget28421www.impactjournals.com/oncotarget
types of cancer, including Ewing's sarcoma [9] and 
colorectal cancer [10], among others. In addition, miR-
34a-5p has been reported to be a direct transcriptional 
target of p53 and is down-regulated in several tumors [11, 
12]. Moreover, miR-34a-5p has been found to inhibit cell 
invasion and migration in vitro [13–16], which suggested 
that miR-34a-5p might play a role in inhibiting tumor 
recurrence.
OS is the most common malignant primary bone 
tumor in children and adolescents [17, 18], but the 
mechanism underlying OS drug resistance remains 
unknown. In addition, despite the above extensive studies 
on miR-34a-5p, the relationship between miR-34a-5p 
and OS drug resistance is still unclear. In this study, we 
found that miR-34a-5p promotes multi-drug resistance 
in OS cells using a systematic analysis to compare multi-
drug sensitive (G-292 and MG63.2) OS cell lines to 
resistant (SJSA-1 and MNNG/HOS) OS cell lines. We 
further showed that miR-34a-5p promotes OS multi-drug 
resistance via repression of the CD117 gene, a newly 
identified direct target of miR-34a-5p. The CD117 gene 
encodes a receptor tyrosine kinase (RTK) belonging to 
the transmembrane RTK family [19] that is involved in 
the tumorigenesis of several neoplasms. CD117 can be 
expressed in a wide variety of malignant tumors, such as 
chronic myeloid leukemia, gastrointestinal stromal tumor, 
malignant melanoma, seminoma, and adenoid cystic 
carcinoma of the salivary gland [20].
In this study, we also determined that the MEF2 
signaling pathway is affected by miR-34a-5p via 
repression of the CD117 gene. The MEF2 signaling 
pathway has roles in different tissues through effects on 
cell differentiation, proliferation, apoptosis, migration, 
shape and metabolism. Altered MEF2 activity plays a 
role in human diseases and has been implicated in the 
development of several cancer types [21]. Taken together, 
our findings will provide a theoretical guide for a clinical 
therapy to combat OS drug resistance as well as provide 
new mechanistic insights into OS drug resistance.
RESULTS
MiR-34a-5p promotes multi-drug resistance 
in OS cells
As follows, the drug resistance of seven OS cell 
lines (G-292, SJSA-1, MG63.2, MG63, Saos-2, U2OS, 
and MNNG/HOS) to doxorubicin (Dox), etoposide (Etop), 
methotrexate (MTX), cisplatin (CDDP), and carboplatin 
(Carb) was evaluated by IC50 profiling, these drugs are 
frequently used for OS therapy. As indicated by the drug 
resistance index, G-292 and MG63.2 were the most 
multi-drug sensitive cell lines, with the lowest IC50 values 
found against Dox, Etop and Carb for G-292 and against 
MTX and CDDP for MG63.2; the relative drug resistance 
indexes of G-292 and MG63.2 were 1.00 and 1.44, 
respectively. In contrast, SJSA-1 and MNNG/HOS were 
the most resistant cell lines with relative drug resistance 
indexes of 27.11 and 20.53, respectively (Figure 1). 
From a RNA-seq-based miR-omic analysis of the G-292, 
MG63.2 and SJSA-1 cell lines, we found that more than 
twenty miRNAs were differentially expressed by more 
than two-fold. Among them, miR-34a-5p was one of the 
most differentially expressed miRNAs in these cells. The 
expression of miR-34a-5p was relatively higher in SJSA-
1 and MNNG/HOS cells than in G-292 and MG63.2 cells 
(Figure 2A and 2B). The results suggested that miR-34a-
5p might promote the multi-drug resistance of OS cells.
CD117 is a direct target of miR-34a-5p 
in OS cells
To identify the target genes of miR-34a-5p that 
are related to the multi-drug resistance of OS cells, we 
predicted the target genes of miR-34a-5p using the 
following websites: Targetscan, miRDB and microRNA.
org. Several common genes were found, and the 
expression of these genes was then measured at both 
the mRNA and protein levels. The CD117 gene was 
selected for further study mainly because its expression is 
correlated with multi-drug resistance, i.e., the CD117 level 
was higher in G-292 and MG63.2 cells than in SJSA-1 and 
MNNG/HOS cells at both the mRNA and protein levels 
(Figure 2C, 2D and 2E).
We then determined the CD117 level in miR-
34a-5p mimic-transfected G-292 and MG63.2 cells and 
antagomiR-transfected SJSA-1 and MNNG/HOS cells for 
comparison with the level in the NC (scramble sequence 
control)-transfected cells. As shown in Figure 3A and 
3B, the transfection of an miR-34a-5p mimic in G-292 
and MG63.2 cells increased the miR-34a-5p level to 
approximately 5.86- and 19.31-fold, respectively, whereas 
the transfection of an miR-34a-5p antagomiR in SJSA-1 
and MNNG/HOS cells significantly decreased the miR-
34a-5p level to 28% and 76%, respectively. Consistent 
with the changes of the miR-34a-5p level, the miR-34a-
5p antagomiR transfection increased both the protein and 
mRNA levels of CD117 in SJSA-1 and MNNG/HOS cells 
(Figure 3C, 3D and 3E). As expected, transfection of the 
miR-34a-5p mimic down-regulated the mRNA and protein 
levels of CD117 (Figure 3C, 3D and 3E) compared with 
those in the NC-transfected G-292 and MG63.2 cells.
To further confirm that CD117 is a direct target 
of miR-34a-5p, we cloned the fragment corresponding 
to nucleotides 760-1311 of the wild-type or mutant 
3’-untranslated region (UTR) of the CD117 gene at the 
downstream of the Renilla luciferase gene in the pGL3-
control vector (Promega) to create pGL3-CD117 UTR 
WT or pGL3-CD117 UTR Mut, respectively (Figure 3F). 
These constructs were transfected into G-292, MG63.2, 
SJSA-1 and MNNG/HOS cells to determine whether 
CD117 is a direct target of miR-34a-5p. We found that 
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Figure 1: Drug resistance profiling of seven osteosarcoma cell lines. A. Experimental scheme. B-F. IC50 values of the five 
indicated chemotherapeutics for seven osteosarcoma cell lines. The cell survival rates were calculated as percentages relative to the mock 
treatment and plotted against lg µM of drug. G. The IC50 (-fold) values relative to those of the most sensitive cell cine (G-292) are presented 
in the table.
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pGL3-CD117-UTR WT led to significantly higher 
luciferase activity in SJSA-1 and MNNG/HOS cells than 
in G-292 and MG63.2 cells (Figure 3G). Furthermore, the 
luciferase activity of pGL3-CD117-UTR WT, but not that 
of the other two constructs, was induced in the antagomiR-
transfected SJSA-1 and MNNG/HOS cells and inhibited 
in the mimic-transfected G-292 and MG63.2 cells (Figure 
3H). Taken together, these results led us to conclude that 
CD117 is indeed a direct target of miR-34a-5p and may 
play roles in OS drug resistance. These data are consistent 
with Siemens et al.’s report [22].
CD117 expression negatively correlates with 
drug resistance in OS cells
The functional connection between miR-34a-5p 
and the CD117 gene in multi-drug resistance was then 
confirmed by comparing the effect on drug-triggered 
cell death in G-292 and MG63.2 cells transfected with 
the miR-34a-5p mimic and in SJSA-1 and MNNG/HOS 
cells transfected with the miR-34a-5p antagomiR. The 
transfection of the miR-34a-5p mimic into G-292 or 
MG63.2 cells significantly increased the drug resistance 
to all tested drugs, except MG63.2 to CDDP. By contrast, 
the transfection of the miR-34a-5p antagomiR into SJSA-
1 or MNNG/HOS cells decreased the drug resistance to 
all tested drugs, except SJSA-1 to CDDP (Figure 4A). 
The si-CD117 was also transfected into G-292 or MG63.2 
cells for testing the drug-resistance effect. The transfection 
of si-CD117 indeed decreased the level of CD117 at 
both the mRNA and protein level (Figure 4B and 4C). 
Following the changes in the CD117 level in G-292 and 
MG63.2 cells, the cell death triggered by all five drugs 
was reduced, except MG63.2 to MTX and CDDP (Figure 
4D). Conversely, transfection of a GFP-tagged CD117 
expression construct increased the CD117 protein level 
in SJSA-1 and MNNG/HOS cells (Figure 4E). The 
resulting drug resistance was significantly decreased for 
all five drugs, except MNNG/HOS to Etop and CDDP, 
whereas the transfection of only GFP showed a marginal 
effect (Figure 4F). In line with its negative effect on drug 
resistance (Figure 4D), the siRNA-mediated degradation 
of CD117 also reduced the number of apoptotic cells 
(Figure 5), this might suggest that the expression of CD117 
reduces drug resistance by inhibiting cell proliferation via 
G2-phase arrest.
Figure 2: The CD117 level is higher in G-292 and MG63. 2 cells than in SJSA-1 and MNNG/HOS cells.The relative miR-34a-5p 
level (fold) in G-292 and MG63.2 cells versus SJSA-1 and MNNG/HOS cells measured by both miR-omic and qRT-PCR analyses is shown 
in a table A. and those measured by qRT-PCR are shown in a plot B. The relative level (fold) of the CD117 gene in G-292 and MG63.2 
cells versus SJSA-1 and MNNG/HOS cells are summarized in a table C., with a plot showing the miR-omic and qRT-PCR analyses D. and 
a figure showing the western blot analysis E. “-” indicates no detection in the omic analysis.
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MiR-34a-5p regulates the activities of the MEF2 
signaling pathway in the context of OS multi-
drug resistance
To further understand the underlying molecular 
mechanisms of OS drug resistance, we used both G-292 
and SJSA-1 cells to measure the activities of the following 
six cancer-related signaling pathways: p53/DNA damage, 
NF-кB, MAPK/ERK, ATF2/ATF3/ATF4, cAMP/PKA 
and MEF2 (Figure 6A). The activities of all six pathways 
differed by more than two-fold between G-292 and SJSA-
1 cells, which indicates that they might have a significant 
role in OS drug resistance. Among them, two pathways, 
p53/DNA damage and NF-кB, showed higher activities in 
SJSA-1 cells, whereas the other four pathways, MAPK/
ERK, ATF2/ATF3/ATF4, cAMP/PKA and MEF2, 
showed higher activities in G-292 cells (Figure 6B). We 
then determined which of the six pathways were also 
affected by forced changes in the CD117 level in both 
G-292 and SJSA-1 cells. As shown in Figure 5, when the 
CD117 level was repressed by a miR-34a-5p mimic or 
si-CD117 in G-292 cells, the activities of ATF2/ATF3/
ATF4, cAMP/PKA and MEF2 were all repressed, which 
correlates well with the positive regulation of these 
pathways by CD117 in G-292 cells (Figure 6C and 6D). 
We also transfected SJSA-1 cells with a miR-34a-5p 
antagomiR or the GFP-CD117 expression construct and 
measured the activities of these six pathways in SJSA-1 
cells. Following the increase of the CD117 level, the NF- 
кB pathway was repressed whereas the MEF2 pathway 
was activated (Figure 6C and 6D), which is in accordance 
with the varying activities of these pathways between 
G-292 and SJSA-1 cells. Overall, only the MEF2 pathway 
was confirmed to be involved in the OS drug resistance 
mediated by the miR-34a-5p repression of the CD117 
gene.
We searched for candidate interactions that could 
connect CD117 with the master transcription factor, MEF2 
Figure 3: CD117 is a direct target of miR-34a-5p in osteosarcoma cells. Level of miR-34a-5p A and B. CD117 mRNA C and 
D. and protein E. levels in the miR-34a-5p mimic (5PM)-transfected G-292 and MG63.2 cells and the miR-34a-5p antagomiR (5PA)-
transfected SJSA-1 and MNNG/HOS cells versus the negative control (NC) cells, as determined by qRT-PCR or western blot analyses. 
Sequences in the UTR region of the CD117 gene targeted by miR-34a-5p, with the hatched section showing the combined area F. The 
relative luciferase activities (fold) of the reporter with the wild-type (WT) or mutant-type (Mut) CD117-UTR or without the UTR (Vec) 
were determined in the osteosarcoma cells transfected with the miR-34a-5p mimic (in G-292 and MG63.2), antagomiR (in SJSA-1 and 
MNNG/HOS) or Mock G and H. sequences. The Renilla luciferase activity of a co-transfected control plasmid was used as a control for 
the transfection efficiency. The representative results from three independent experiments are shown. *P value<0.05 by Student’s t-test.
Oncotarget28425www.impactjournals.com/oncotarget
(Figure 7), using GeneMANIA [23]. In total, 18 interacting 
genes of CD117 were found in both GeneMANIA and the 
UniHI database [24]. Additional data mining was used to 
build a potential connection network describing the series 
of interactions (Figure 7). In this working model, the 
CD117 gene regulates the MEF2 signaling pathway via an 
interaction with three genes, GAB2, PRKCA and SH2B3.
MiR-34a-5p promotes both the growth and 
Dox drug resistance of G-292 cells and SJSA-1-
derived tumor xenografts in nude mice
An intratumoral injection of miR-34a-5p agomiR/
antagomiR, the scramble sequence control (Mock) or 
phosphate-buffered saline (PBS) into G-292/ SJSA-1-
Figure 4: Effects of a forced reversal of the miR-34a-5p or CD117 levels on the drug resistance of G-292 and SJSA-1 
cells. Cell death triggered by an IC50 dose of drug in G-292, MG63.2, SJSA-1 and MNNG/HOS cells transfected with a miR-34a-5p mimic 
(5PM) or antagomiR (5PA) versus the negative control (NC) assayed 72 hr after treatment with the IC50 dose of drugs A. Levels of CD117 
mRNA determined by qRT-PCR in the siRNA-transfected G-292 and MG63.2 cells versus the NC-transfected cells B. CD117 protein 
level (western blot analysis) in the siRNA-transfected versus the NC-transfected G-292 and MG63.2 cells C. Cell survival of the G-292 
and MG63.2 cells transfected with siRNA relative to that of the NC-transfected G-292 and MG63.2 cells 72 hr after a treatment with the 
IC50 dose of drugs D. CD117 protein level (western blot analysis) in the GFP-tagged overexpression construct-transfected versus the NC-
transfected SJSA-1 and MNNG/HOS cells E. Cell survival of the SJSA-1 and MNNG/HOS cells transfected with miR-34a-5p antagomiR 
(5PA) relative to that the NC-transfected SJSA-1 cells assayed 72 hr post-treatment with the IC50 dose of drugs F. *P value < 0.05; **P 
value < 0.01.
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derived tumors was initiated on the tenth day and repeated 
five times over 3 days. The intraperitoneal injection of 
PBS or Dox began on day 25 in either the G-292 or SJSA-
1 group and was repeated four times over 3 days (Figure 
8A). The tumor mass was weighed at the end of this study. 
SJSA-1-derived tumors were approximately 2-fold heavier 
than G-292-derived tumors (Figure 8B-8F), suggesting 
that miR-34a-5p promotes tumor growth in vivo. 
Conversely, an intratumoral injection of the miR-34a-5p 
antagomiR into the SJSA-1 cell-derived tumor xenograft 
resulted in the opposite phenotype. A similar effect was 
observed for agomiR in G-292 tumors. Therefore, miR-
34a-5p is capable of promoting in vivo tumor growth.
Consistent with the observation that SJSA-1 was 
more Dox resistant than G-292 cells in culture (Figure 
1), after an intraperitoneal injection of Dox, the G-292 
tumors were much smaller than the SJSA-1 tumors 
(Figure 8B). Furthermore, the tumor weight for the miR-
34a-5p antagomiR/Dox in SJSA-1 mice was smaller 
than the weight for the miR-34a-5p antagomiR/Mock 
counterpart, and the opposite was true for the Dox-treated 
group of G-292 cells with or without miR-34a-5p agomiR 
transfection (Figure 8C-8F). These results indicated that 
miR-34a-5p compromised the tumor-inhibition capability 
of Dox.
Further confirmation of the miR-34a-5p role in the 
Dox resistance of OS came from the immunohistological 
analysis of the CD117 and Ki67 (an indicator of tumor 
cell proliferation) in the tumor sections of the Dox-treated 
versus PBS-treated mice (Figure 8G). The intratumoral 
injection of an miR-34a-5p agomiR (into G-292)/
antagomiR (into SJSA-1) indeed led to the expected 
changes in the CD117 level in the tumor sections (Figure 
8G), which confirmed that miR-34a-5p has a profound 
positive effect on both the growth and drug resistance of 
OS cell-derived tumor xenografts in nude mice.
DISCUSSION
Our previous studies have shown that miR-193a-3p 
is involved in multi-drug resistance in both hepatocellular 
carcinoma [25] and bladder cancer [26, 27] via the repression 
of different target genes, including SRSF2, PLAU, HIC2 
and LOXL4 [26, 27]. In the present work, we showed that 
miR-34a-5p is also involved in the multi-drug resistance of 
OS. MiR-34a-5p is up-regulated in multi-chemoresistant 
(SJSA-1 and MNNG/HOS) cell lines compared to the 
multi-chemosensitive (G-292 and MG63.2) OS cell lines 
(Figure 1 and 2). We next performed a comparative RNA-
seq omic analysis of the SJSA-1, G-292 and MG63.2 cell 
lines and identified a panel of genes that are differentially 
expressed, including the CD117 gene, which exhibits a 
negative correlation with drug resistance (Figure 2). Both 
the roles and mechanisms of the CD117 gene in the context 
Figure 5: Effects of the forced reversal of both the miR-34a-5p and CD117 levels on the apoptosis of G-292 cells, with 
a graph of the analyzed data and plots of the original FACS data. *P value < 0.05; **P value < 0.01.
Oncotarget28427www.impactjournals.com/oncotarget
Figure 6: Signaling pathways regulated by miR-34a-3p and its downstream gene, CD117. Experimental scheme A. Relative 
activities (mean ± S.D.) of six pathways that differed by more than two-fold between G-292 and SJSA-1 cells B. Relative pathway activities 
in the miR-34a-5p mimic (5PM)-transfected cells versus the NC transfected G-292 cells and miR-34a-5p antagomiR (5PA)-transfected 
cells versus the NC-transfected SJSA-1 cells C. Relative pathway activities in the cells transfected with si-CD117 and GFP-CD117 versus 
the NC-transfected G-292 and SJSA-1 cells D. The boxes indicatethe pathways that failed to respond in an expected manner.
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of OS drug resistance were systematically evaluated in both 
cultured cells and tumor xenografts in nude mice. Notably, 
miR-34a-5p was reported to suppress colorectal cancer 
metastasis and inhibit recurrence of colorectal cancer [28]. 
This suggests that miR-34a-5p might play distinct roles in 
different types of cancers. In addition, miR-34a was also 
found to inhibit the metastasis of osteosarcoma cells by 
repressing the expression of CD44, which indicates that 
miR-34a plays a tumor suppressor role [29]. Two different 
OS cells, the highly metastatic F5M2 and the low metastatic 
F4 cells were used to test the invasion and metastasis. In our 
work, we found that miR-34a-5p promotes the multi-drug 
resistance of OS by targeting the CD117 gene. Our results 
together with previous report suggest that miR-34a might 
play multi-functional roles by targeting different genes in the 
OS pathology. More investigations are needed to elucidate 
the fine regulation mechanism of miR-34a in OS pathology.
The CD117 gene encodes a type III RTK [19] and 
is an important mediator/initiator of several signaling 
cascades [30]. In addition, CD117 performs numerous 
functions in the tumorigenesis of several neoplasms, such 
as leukemia [31], glioblastoma [32], melanoma [33], 
and lung [34] and breast cancer [35]. Furthermore, a few 
studies have suggested that CD117 expression may be 
helpful in the differential diagnosis between high-grade 
neuroendocrine carcinomas of lungand non–small cell 
Figure 7: Simplified map showing an analysis of the interaction between the target gene (CD117) and the MEF2 
pathway generated by GeneMANIA (http://genemania.org/). The orange solid lines specify a direct physical interaction among 
these proteins. The gray solid lines indicate genetic interactions among these proteins.
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Figure 8: Effect of miR-34a-5p on the in vivo growth and Dox drug resistance of SJSA-1 and G-292-derived xenografts 
in nude mice. A., Experimental scheme: SJSA-1 or G-292 cells were subcutaneously injected at two points on the back of each nude 
mouse, with 2 sites/mouse, 6 mice for SJSA-1, and 6 mice for G-292. From the 10th day after cell injection, all six SJSA-1-generated 
tumors on the left back of the nude mice were intratumorally injected with 2 nM miR-34a-5p agomiR, and the six right back sites were 
injected with 2 nM Mock; G-292-generated tumors on the left back of the nude mice were injected with 4Nm miR-34a-5p antagomiR, and 
the six right sites were injected with 4 nM Mock; this process was repeated five times within 3 days. From the 25th day after cell injection, 
3 SJSA-1 mice and 3 G-292 mice received Dox (2.5 mg/kg) intraperitoneally once every 3 days, for a total of 4 injections over 12 days. 
The remaining 6 mice (3 from SJSA-1 and 3 from G-292) received PBS as a mock treatment control. B., Image of representative mice 
with tumors on day 40. C., D., E and F., The mean ± SD of the tumor weight of the tumor for the same treatment was calculated, plotted 
(*, P value< 0.05), and summarized. G., The protein levels of CD117 and Ki67 in each group were determined by immunostaining and 
summarized in the table (Magnification: 200×).
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lung tumors [36, 37]. Despite the extensive studies of 
CD117, the role of CD117 in OS remains unclear. In this 
study, we clearly demonstrated that the down-regulation 
of CD117 mediated by miR-34a-5p might be one of the 
reasons for OS drug resistance. CD117 may also regulate 
other processes, including cell adhesion, differentiation and 
migration, which are significant for cancer development 
and treatment [38]. Here, we propose that CD117 mediates 
OS drug resistance via the MEF2 signaling pathway. The 
MEF2 pathway is activated in several types of cancer 
through different mechanisms. The detailed mechanisms 
for how CD117 affects the MEF2 pathway and the links 
between the MEF2 pathway and OS drug resistance still 
need to be elucidated. In addition, for the interaction of 
CD117 and miR-34a-5p with numerous signaling pathways, 
more detailed analyses are necessary to illuminate the 
detailed molecular mechanism of this regulation.
As previously reported, CD117 is a cancer stem 
cell marker and thus associated with increased drug 
resistance in several human cancers, including OS [39]. 
To investigate whether miR-34a-5p and CD117 affect 
the colony-forming ability of G-292 cells in vitro, 
we performed colony-forming and spheroids assays 
(supplementary Figure 1). Cells treated with miR-34a-5p 
formed clones and spheroids that were more numerous 
and larger than those of the control groups. In contrast, 
cells treated with si-CD117 formed much smaller clones 
and spheroids than did the control groups. As expected, 
the addition of the siRNAs for cancer stem markers, si-
OCT4 or si-NANOG, decreased the size and quantity 
of the clones and spheroids. The results suggested that 
miR-34a-5p promotes cell proliferation, leading to the 
formation of larger clones, which is in accordance with 
the drug resistance-promoting effect. To test whether 
the promoting effect of miR-34a-5p-mediated cell 
proliferation is conducted by OCT4 and NANOG, we 
tested the expression levels of OCT4 and NANOG in OS 
cells transfected with either miR-34a-5p antagomiR or 
mimic. The transfection of miR-34a-5p antagomiR into 
SJSA-1 and MNNG/HOS cells significantly increased 
the expression of OCT4 and NANOG, whereas the 
transfection of miR-34a-5p mimic into G-292 or MG63.2 
cells decreased the expression of OCT4 and NANOG 
(supplementary Figure 2). OCT4 and NANOG showed 
similar expression pattern with CD117 against miR-
34a-5p antagomiR or mimic, which also indicates 
that the promoting effect of miR-34a-5p-mediated 
cell proliferation is a complicated event. The detailed 
mechanism remains to be clarified. Of note, CD117 
showed a promoting effect on cell proliferation similar to 
that of the cancer stem cell markers OCT4 and NANOG, 
which also suggested that CD117 might function as a 
cancer stem marker in OS; however, CD117 showed a 
negative regulation of OS drug resistance in this study. 
CD117, as a potential cancer stem marker, could also 
impair OS drug resistance. More investigations are needed 
to elucidate the detailed mechanism for this complicated 
regulation in OS.
MATERIALS AND METHODS
Cell lines
The following seven OS cell lines were purchased 
from ATCC: G-292 (ATCC NO. CRL-1423), SJSA-1 
(ATCC NO.CRL-2098), MG63 (ATCC NO.CRL-1427), 
Saos-2 (ATCC NO.HTB-85), U2OS (ATCC NO. 40342) 
and MNNG/HOS (ATCC NO. 1547). Another cell line, 
MG63.2, which was derived from MG63, was kindly 
provided by Dr. Luu from the University of Chicago [40]. 
All of the cell lines were cultured in Dulbecco’s modified 
Eagle’s medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum (Invitrogen) 
and 1% glutamine at 37°C in 5% CO2.
RNA-seq analysis
RNA-seq analysis was performed by BGI-Tech of 
China, and RNA-seq library preparation and sequencing 
were performed by BGI (Shenzhen, China). Following 
purification, the RNA was fragmented using divalent 
cations at an elevated temperature, and first-strand 
cDNA was synthesized using random hexamer primers 
and Superscript TMIII (Invitrogen™, Carlsbad, CA, 
USA). Second-strand cDNA was synthesized using 
buffer, dNTPs, RNaseH, and DNA polymerase I. Short 
fragments were purified with a QiaQuick PCR extraction 
kit (Qiagen) and resolved with EB buffer for end repair 
and poly (A) addition. The short fragments were 
subsequently connected using sequencing adapters. After 
agarose gel electrophoresis, suitable fragments were used 
as templates for PCR amplification. During the QC steps, 
an Agilent 2100 Bioanalyzer and an ABI StepOnePlus 
Real-Time PCR System were used for the quantification 
and qualification of the sample library. Finally, the 
library (200 bp insert) was sequenced using an Illumina 
HiSeq 2000 (Illumina Inc., San Diego, CA, USA). The 
single-end library was prepared following the protocol 
of the Illumina TruSeq RNA Sample Preparation Kit 
(Illumina) [41].
RNA analysis
Total RNA was isolated from the cells at the 
logarithmic phase using Trizol (Tiangen Biotech Co., 
Ltd., Beijing, China). For the mRNA analysis, cDNA 
primed by oligo-dT was made with a prime Script RT 
reagent kit (Tiangen Biotech Co., Ltd., Beijing, China), 
and the mRNA level of the CD117 gene was quantified 
using duplex-qRT-PCR analysis where the Taqman probes 
with different fluorescence for β-actin (provided by Shing 
Gene, Shanghai, China) were used in the FTC-3000P 
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PCR instrument (Funglyn Biotech Inc., Canada). Using 
the 2−ΔΔCt method, normalization to the β-actin level was 
performed before the relative levels of the target genes 
were compared. The sequences of the primers and probes 
used for the qRT-PCR analysis are:
hCD117 F: 5′- AATATGAAGCATTCCCCAAACC-3′
hCD117 R: 5′- CTTCGGTGCCTTTTAATCTCG-3′
hCD117 probe: 5′-CY5- CACCAGCAGTGGATCT
ATATGAACAGAACC-3′
hACTB F: 5′-GCCCATCTACGAGGGGTATG-3′
hACTB R: 5′-GAGGTAGTCAGTCAGGTCCCG-3′
hACTB probe: 5′HEX-CCCCCATGCCATCCTG 
CGTC-3′
Bulge-Loop™ miRNA qRT-PCR
For detecting and quantifying the expression of 
specific miRNAs, RNA was reverse transcribed using a 
Bulge-Loop™ miRNA qRT-PCR Primer Set (Ribobio) and 
quantified by SYBR Green-based real-time PCR analysis 
in the FTC-3000P (FUNGLYN BIOTECH INC., Canada). 
The Ct values of the target miRs were normalized to the Ct 
values of U6 RNA before quantification using the 2−ΔΔCt 
method.
Chemotherapeutics
The chemotherapeutic drugs used in this paper 
are of clinical grade [26, 42, 43] (NCI Dictionary of 
Cancer Terms, http://www.cancer.gov/dictionary), Dox: 
doxorubicin (Haizheng, Zhejiang, China); Etop: etoposide 
(Hengrui, Jiangsu, China); MTX: Methotrexate (Lingnan, 
Guangdong, China); CDDP: cisplatin (Haosen, Jiangsu, 
China) and Carb: carboplatin (Qilu, Shandong, China).
Drug resistance profiling (IC50 determination)
For a thiazolyl blue tetrazolium blue (MTT)-based 
cell proliferation assay, cells in the logarithmic phase 
of growth were seeded in triplicate in 96-well plates at a 
density of 0.5×104 cells/well and treated with 4-fold serially 
diluted drugs for 72 hr. Then, 10 μl (5 mg/ml) of MTT salt 
(Sigma) was added to the corresponding well, the cells were 
incubated at 37°C for an additional 4 hr, and the reaction 
was stopped by lysing the cells with 150 μl of DMSO for 10 
min. The optical density was measured at 570 nm. Both the 
linear regression parameters and the IC50 (the concentration 
of drug required to kill 50% of the cells) values with the no-
drug control as the reference were calculated. The relative 
drug resistance was presented as the fold change in the IC50 
of the cell lines relative to the lowest IC50.
Transfection of the mimic/antagomiR/siRNA/
overexpression plasmid
The mimic, agomiR, antagomiR, siRNA, scramble 
sequence control (NC) and riboFECT CP transfection 
kit were supplied by Guangzhou Ribobio, China. The 
expression construct for CD117 (EX-Z4357-M98) 
with a GFP tag was supplied by Guangzhou Fulengen, 
China. Transfection of both ribonucleic acid reagents 
or plasmids mentioned in this paper and the reporter 
plasmids in Cignal Finder™ Pathway Reporter Arrays 
(SABiosciences, USA) was performed according to the 
manufacturer’s instructions. The sequences used in this 
study are as follows:
si-CD117:
5’-GGAUGAAACGAAUGAGAAU dTdT-3’
3’-dTdT CCUACUUUGCUUACUCUUA-5’
hsa-miR-34a-5p
antagomiR: 5’ACAACCAGCUAAGACACUGCCA 3’
mimics:
sense 5’UGGCAGUGUCUUAGCUGGUUGU 3’
antisense 5’ACAACCAGCUAAGACACUGCCA 3’
Chemically modified mimic oligonucleotides 
(agomiR) were synthesized to regulate the miR-34a-5p 
expression in vivo. The 3′ end of the oligonucleotides 
was conjugated to cholesterol, and all of the bases were 
2′-OMe modified. The agomiR oligonucleotides were 
deprotected, desalted and purified by high-performance 
liquid chromatography.
Luciferase reporter assay
A portion of the CD117 3’-UTR (552 bp, 760-1311 
from a 2172-bp full length sequence) combined with the 
target sequence or the mutant target sequence for miR-
34a-5p was cloned into the 3’ end of the luciferase-coding 
sequence of pGL3 (Invitrogen) to construct pGL3-luc-
CD117 WT and pGL3-luc-CD117 Mut, respectively. The 
constructs were confirmed by DNA sequencing. Cells were 
seeded in 96-well plates at approximately 1×104 cells per 
well and transfected with a mixture of 50 ng of pGL3-luc 
CD117 WT or Mut, 5 ng of Renilla plus 5 pmol of mimic 
or NC nucleotides, with the riboFECT CP transfection 
kit according to the manufacturer’s instructions. Both the 
firefly and Renilla luciferase activities were measured 24 
hr after transfection using the Dual-Luciferase Reporter 
Assay System (Promega) and a Promega GloMax 20/20 
luminometer. The relative firefly luciferase activities of 
the UTR construct and pathway reporter constructs were 
analyzed as previously reported [26].
Signaling pathway analysis
Constructs for the reporters of six signaling pathway, 
p53/DNA damage, NF-κB, MAPK/ERK, cAMP/PKA, 
ATF2/ATF3/ATF4 and MEF2 pathways, were obtained 
from SABiosciences (USA) and analyzed according to 
the manufacturer’s instructions. Briefly, the cells were 
transfected in triplicate with each firefly luciferase reporter 
construct in combination with the Renilla luciferase-based 
control construct using the riboFECT CP transfection 
reagent, and both the luciferase activities were measured 
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in the cell extracts 24 hr after transfection. The luciferase 
activities (luciferase unit) of the pathway reporter relative 
to those of the negative control in the transfected cells 
were calculated as a measurement of the pathway activity.
Apoptosis analysis
Cells were harvested and rinsed with PBS twice. 
Then, 5 μl of FITC-labeled enhanced annexin V and 5 μl 
(20 μg/ml) of propidium iodide were added to a 100 μl 
cell suspension. After incubation in the dark for 15 min at 
room temperature, the samples were diluted with 100 μl of 
PBS. Flow cytometry was performed on a FACSCalibur 
instrument. The results were analyzed according to 
the manufacturer’s instructions. The experiments were 
performed independently three times, and a representative 
is shown.
Western blot analysis of protein
Cells were lysed with lysis buffer (60 mM Tris-HCl, 
pH 6.8, 2% SDS, 20% glycerol, 0.25% bromophenol blue, 
and 1.25% 2-mercaptoethanol) and heated at 100°C for 10 
min before electrophoresis. Anti-CD117 (AM2137b) was 
purchased from Abgent, and anti-GAPDH (AM1020a) 
and HRP goat anti-mouse IgG antibody (LP1002a) were 
provided by Wuxiphama, Shanghai, China. The target 
bands were revealed by an enhanced chemiluminescence 
reaction (Pierce), and the density (level) of the proteins 
relative to the GAPDH band was quantified using a Gel-
Pro Analyzer (Media Cybernetics).
Bioinformatics analysis
CD117 and a representative gene, MEF2, in the 
MEF2 pathway were used as query genes to predict 
potential interactions using the GeneMANIA database 
(http://genemania.org/). GeneMANIA uses a fast heuristic 
algorithm to integrate functional association networks 
containing all input genes. To simplify the model, the 
shortest paths between query genes were extracted from 
the networks. We first chose the interactions reported in 
the literature to obtain the true functional role of each 
interaction in the connected network of all query genes.
In vivo studies
Animal experiments were undertaken in accordance 
with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals. BALB/c male nude 
miceof 3-4 weeks of age were used for this study. SJSA-1 
or G-292 cells were embedded in BD Matrigel™ Matrix 
(Becton, Dickinson, NJ, USA) and subcutaneously 
injected into the two sites on the backs of mice as 
follows: 4×106 cells/site for SJSA-1, 1×107 cells/site for 
G-292, 2 sites/mouse, 6 mice for SJSA-1, and 6 mice 
for G-292. From the 10th day after cell injection, all six 
SJSA-1-generated tumors on the left back of the nude 
mice were intratumorally injected with 2 nM miR-34a-
5p antagomiR, and the six tumors on the right back were 
injected with 2 nM Mock. G-292-generated tumors on the 
left backs of nude mice were injected with 4 nM miR-34a-
5p agomiR, and the six tumors on the right of the backs 
were injected with 4 nM Mock. These injections were 
repeated five times in 3 days. Three mice from SJSA-1 
and 3 from G-292 intraperitoneally received Dox (2.5 mg/
kg) once in 3 days. The remaining 6 mice (3 from SJSA-
1 and 3 from G-292) received phosphate-buffered saline 
(PBS) as a mock treatment control, and these injections 
were repeated four times. The mice were humanely 
sacrificed on day 40, and the tumors were weighed and 
photographed. The tumor weight was reported as the mean 
± S.D.
The expression of CD117 protein was measured 
using immunochemical analysis of 5-mm slices of 
formalin-fixed paraffin-embedded tumor xenografts 
from the nude mice. To avoid inter-treatment bias, 
the tissue slides from all six groups were placed on a 
single slide and simultaneously subjected to the same 
immunostaining. Antigens were retrieved by pretreating 
dewaxed sections in a microwave oven at 750 watts for 5 
min in citrate buffer (pH 6) and processed with the Super 
Sensitive Link-Labeled Detection System (Biogenex, 
Menarini, Florence, Italy). The enzymatic activities 
were determined using 3-amino-9-ethylcarbazole (Dako, 
Milan, Italy) as a chromogenic substrate. Following 
counterstaining with Mayer hematoxylin (Invitrogen), 
the slides were mounted in aqueous mounting medium 
(glycergel, Dako). Pictures were taken usinga LEICA DM 
4000B microscope, the relative level of each protein was 
calculated using LEICA software, and the percentage of 
Mock-treated relative to chemotherapeutic-treated tumors 
was calculated and plotted. The animal study proposal 
was approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Science and 
Technology of China. All of the mouse experimental 
procedures were performed in accordance with the 
Regulations for the Administration of Affairs Concerning 
Experimental Animals approved by the State Council of 
People’s Republic of China.
Sphere formation assay
For induction of sphere formation, the G-292 cells 
were transfected with either a miR-34a-5p mimic or 
control oligo. after 24 hr, the cells were trypsinized, and 
1×104 cells were seeded in a six-well plate coated with 
attachment-preventing PolyHEMA (Sigma) using a 3 
ml of sphere medium consisting of DMEM-F12 (Gibco) 
supplemented with B27 supplement (1:50, Gibco), EGF 
(20 ng/ml, Invitrogen), and bFGF (20 ng/ ml, Invitrogen), 
which was added to the medium every 3 days. Then, the 
sphere formation experiment was performed. The number 
of colonies larger than 50 μm in diameter was determined 
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after ten days. Representative pictures were taken using a 
LEICA DM 4000B microscope at 40-fold magnification.
Statistical analysis
The data are presented as the means, and the error 
bars indicate the S.D. All of the statistical analyses were 
performed using Excel (Microsoft, Redmond, WA, USA). 
A two-tailed Student’s t-test, a one-way analysis of 
variance or Mann–Whitney U test was used to calculate 
statistical significance. A P value of <0.05 was considered 
significant.
ACKNOWLEDGMENTS
This work was supported by the National Natural 
Science Foundation of China (81372868 granted to 
SBC), the Natural Science Foundation of Anhui Province 
(1408085MH204, 1608085MH224 and 1608085MH223 
granted to SBC, YGP and HYW, respectively).
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression 
of protein synthesis by miRNAs: how many mechanisms? 
Trends in cell biology. 2007; 17:118-126.
2. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck 
D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, 
Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA 
expression profiles classify human cancers. Nature. 2005; 
435:834-838.
3. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, 
Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt 
RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini 
M, et al. A microRNA expression signature of human 
solid tumors defines cancer gene targets. Proceedings of 
the National Academy of Sciences of the United States of 
America. 2006; 103:2257-2261.
4. Allen KE, Weiss GJ. Resistance may not be futile: microRNA 
biomarkers for chemoresistance and potential therapeutics. 
Molecular cancer therapeutics. 2010; 9:3126-3136.
5. He H, Ni J, Huang J. Molecular mechanisms of 
chemoresistance in osteosarcoma (Review). Oncology 
letters. 2014; 7:1352-1362.
6. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman 
ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au 
GK, Liu CG, Calin GA, Croce CM, Harris CC. MicroRNA 
expression profiles associated with prognosis and 
therapeutic outcome in colon adenocarcinoma. Jama. 2008; 
299:425-436.
7. Yang L, Li N, Wang H, Jia X, Wang X, Luo J. Altered 
microRNA expression in cisplatin-resistant ovarian cancer 
cells and upregulation of miR-130a associated with MDR1/
P-glycoprotein-mediated drug resistance. Oncology reports. 
2012; 28:592-600.
8. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, 
Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, 
Ju J. Mechanism of chemoresistance mediated by miR-140 
in human osteosarcoma and colon cancer cells. Oncogene. 
2009; 28:4065-4074.
9. Nakatani F, Ferracin M, Manara MC, Ventura S, Del 
Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila 
S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra 
M, Scotlandi K. miR-34a predicts survival of Ewing's 
sarcoma patients and directly influences cell chemo-
sensitivity and malignancy. The Journal of pathology. 
2012; 226:796-805.
10. Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, 
Sung JJ, Shen L, Yu J. miR-34a-5p suppresses colorectal 
cancer metastasis and predicts recurrence in patients with 
stage II/III colorectal cancer. Oncogene. 2015; 34:4142-4152.
11. Hermeking H. p53 enters the microRNA world. Cancer cell. 
2007; 12:414-418.
12. Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: 
the feedback loop. Cell Cycle. 2009; 8:712-715.
13. Wu J, Wu G, Lv L, Ren YF, Zhang XJ, Xue YF, Li G, 
Lu X, Sun Z, Tang KF. MicroRNA-34a inhibits migration 
and invasion of colon cancer cells via targeting to Fra-1. 
Carcinogenesis. 2012; 33:519-528.
14. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L. 
Restoration of tumor suppressor miR-34 inhibits human 
p53-mutant gastric cancer tumorspheres. BMC cancer. 
2008; 8:266.
15. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. miR-
34a inhibits migration and invasion by down-regulation of 
c-Met expression in human hepatocellular carcinoma cells. 
Cancer letters. 2009; 275:44-53.
16. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz 
T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, 
Ramirez J, Monzo M. miR-34a as a prognostic marker of 
relapse in surgically resected non-small-cell lung cancer. 
Carcinogenesis. 2009; 30:1903-1909.
17. Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. 
Current opinion in pharmacology. 2014; 16:15-23.
18. Yang J, Zhang W. New molecular insights into 
osteosarcoma targeted therapy. Current opinion in 
oncology. 2013; 25:398-406.
19. Ni S, Huang D, Chen X, Huang J, Kong Y, Xu Y, Du X, 
Sheng W. c-kit gene mutation and CD117 expression in 
human anorectal melanomas. Human pathology. 2012; 
43:801-807.
20. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, 
Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, 
Oncotarget28434www.impactjournals.com/oncotarget
Sauter G. Prevalence of KIT expression in human tumors. 
Journal of clinical oncology. 2004; 22:4514-4522.
21. Pon JR, Marra MA. MEF2 transcription factors: 
developmental regulators and emerging cancer genes. 
Oncotarget. 2016; 7:2297-2331. doi: 10.18632/oncotarget. 
6223.
22. Siemens H, Jackstadt R, Kaller M, Hermeking H. 
Repression of c-Kit by p53 is mediated by miR-34 and is 
associated with reduced chemoresistance, migration and 
stemness. Oncotarget. 2013; 4:1399-1415. doi:10.18632/
oncotarget.1202.
23. Montojo J, Zuberi K, Rodriguez H, Bader GD, Morris Q. 
GeneMANIA: Fast gene network construction and function 
prediction for Cytoscape. F1000Research. 2014; 3:153.
24. Kalathur RK, Pinto JP, Hernandez-Prieto MA, Machado 
RS, Almeida D, Chaurasia G, Futschik ME. UniHI 7: an 
enhanced database for retrieval and interactive analysis 
of human molecular interaction networks. Nucleic acids 
research. 2014; 42(Database issue):D408-414.
25. Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, Ding X, 
Xu H, Chen X, Zhu J. DNA methylation-regulated miR-
193a-3p dictates resistance of hepatocellular carcinoma 
to 5-fluorouracil via repression of SRSF2 expression. The 
Journal of biological chemistry. 2012; 287:5639-5649.
26. Lv L, Deng H, Li Y, Zhang C, Liu X, Liu Q, Zhang D, 
Wang L, Pu Y, Zhang H, He Y, Wang Y, Yu Y, Yu T, Zhu 
J. The DNA methylation-regulated miR-193a-3p dictates 
the multi-chemoresistance of bladder cancer via repression 
of SRSF2/PLAU/HIC2 expression. Cell death & disease. 
2014; 5:e1402.
27. Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y, Xiao J, Qian 
L, Zhao W, Liu Q, Zhang D, Wang Y, Zhang H, He Y, 
Zhu J. miR-193a-3p regulates the multi-drug resistance 
of bladder cancer by targeting the LOXL4 gene and the 
Oxidative Stress pathway. Molecular cancer. 2014; 13:234.
28. Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, 
Sung JJ, Shen L, Yu J. miR-34a-5p suppresses colorectal 
cancer metastasis and predicts recurrence in patients 
with stage II/III colorectal cancer. Oncogene. 2015; 
34:4142-4152.
29. Zhao H, Ma B, Wang Y, Han T, Zheng L, Sun C, Liu T, 
Zhang Y, Qiu X, Fan Q. miR-34a inhibits the metastasis of 
osteosarcoma cells by repressing the expression of CD44. 
Oncology reports. 2013; 29:1027-1036.
30. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman 
J, Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman 
D, et al. Molecular cloning of mast cell growth factor, a 
hematopoietin that is active in both membrane bound and 
soluble forms. Cell. 1990; 63:235-243.
31. Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, 
Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin 
JD. Expression and functional role of the proto-oncogene 
c-kit in acute myeloblastic leukemia cells. Blood. 1991; 
78:2962-2968.
32. Mahzouni P, Jafari M. The study of CD117 expression in 
glial tumors and its relationship with the tumor-type and 
grade. J Res Med Sci. 2012; 17:159-163.
33. Montone KT, van Belle P, Elenitsas R, Elder DE. Proto-
oncogene c-kit expression in malignant melanoma: protein 
loss with tumor progression. Mod Pathol. 1997; 10:939-944.
34. Krystal GW, Hines SJ, Organ CP. Autocrine growth of 
small cell lung cancer mediated by coexpression of c-kit 
and stem cell factor. Cancer research. 1996; 56:370-376.
35. Hines SJ, Organ C, Kornstein MJ, Krystal GW. 
Coexpression of the c-kit and stem cell factor genes in 
breast carcinomas. Cell growth & differentiation. 1995; 
6:769-779.
36. Arber DA, Tamayo R, Weiss LM. Paraffin section detection 
of the c-kit gene product (CD117) in human tissues: value 
in the diagnosis of mast cell disorders. Human pathology. 
1998; 29:498-504.
37. Gibson PC, Cooper K. CD117 (KIT): a diverse protein with 
selective applications in surgical pathology. Advances in 
anatomic pathology. 2002; 9:65-69.
38. Sattler M, Salgia R. Targeting c-Kit mutations: basic 
science to novel therapies. Leukemia research. 2004; 28 
Suppl 1:S11-20.
39. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, 
Pochampally RR, Iwakuma T. CD117 and Stro-1 identify 
osteosarcoma tumor-initiating cells associated with 
metastasis and drug resistance. Cancer research. 2010; 
70:4602-4612.
40. Su Y, Luo X, He BC, Wang Y, Chen L, Zuo GW, Liu B, Bi 
Y, Huang J, Zhu GH, He Y, Kang Q, Luo J, Shen J, Chen 
J, Jin X, et al. Establishment and characterization of a new 
highly metastatic human osteosarcoma cell line. Clinical & 
experimental metastasis. 2009; 26:599-610.
41. Tarazona S, Garcia-Alcalde F, Dopazo J, Ferrer A, Conesa 
A. Differential expression in RNA-seq: a matter of depth. 
Genome research. 2011; 21:2213-2223.
42. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein 
TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani 
N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, et 
al. Subtype and pathway specific responses to anticancer 
compounds in breast cancer. Proceedings of the National 
Academy of Sciences of the United States of America. 
2012; 109:2724-2729.
43. Andrisano V, Bartolini M, Gotti R, Cavrini V, Felix G. 
Determination of inhibitors' potency (IC50) by a direct 
high-performance liquid chromatographic method on 
an immobilised acetylcholinesterase column. Journal of 
chromatography B, Biomedical sciences and applications. 
2001; 753:375-383.
